<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lipid-Lowering Competitors - Comprehensive Analysis</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .main-container {
            max-width: 1600px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .main-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 30px 40px;
            position: relative;
            overflow: hidden;
        }
        
        .main-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.05);
            transform: rotate(45deg);
        }
        
        .main-title {
            font-size: 36px;
            font-weight: bold;
            margin-bottom: 10px;
            position: relative;
            z-index: 1;
        }
        
        .main-subtitle {
            font-size: 18px;
            opacity: 0.95;
            position: relative;
            z-index: 1;
        }
        
        .drug-nav-container {
            display: flex;
            background: #f0f0f0;
            overflow-x: auto;
            white-space: nowrap;
            border-bottom: 3px solid #ddd;
        }
        
        .drug-nav-tab {
            padding: 15px 25px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 15px;
            font-weight: 600;
            color: #555;
            transition: all 0.3s;
            white-space: nowrap;
            position: relative;
        }
        
        .drug-nav-tab:hover {
            background: rgba(102, 126, 234, 0.1);
            color: #667eea;
        }
        
        .drug-nav-tab.active {
            color: white;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
        }
        
        .drug-content {
            display: none;
        }
        
        .drug-content.active {
            display: block;
        }
        
        .drug-header {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1) 0%, rgba(118, 75, 162, 0.1) 100%);
            padding: 30px 40px;
            border-bottom: 2px solid #e0e0e0;
        }
        
        .drug-name {
            font-size: 32px;
            font-weight: bold;
            color: #333;
            margin-bottom: 5px;
        }
        
        .drug-subtitle {
            font-size: 18px;
            color: #666;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 16px;
            color: #888;
        }
        
        .status-badge {
            display: inline-block;
            background: #667eea;
            color: white;
            padding: 6px 12px;
            border-radius: 20px;
            margin-top: 10px;
            font-size: 14px;
            font-weight: 600;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 12px 20px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 14px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(102, 126, 234, 0.1);
        }
        
        .nav-tab.active {
            color: #667eea;
            border-bottom: 3px solid #667eea;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 30px 40px;
            min-height: 500px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 25px;
            margin: 25px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 12px;
            padding: 20px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.08);
            border: 1px solid #e0e0e0;
        }
        
        .info-card-title {
            font-size: 16px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 28px;
            height: 28px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
            line-height: 1.5;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1) 0%, rgba(118, 75, 162, 0.1) 100%);
            border-left: 4px solid #667eea;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
            font-size: 16px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
            font-size: 14px;
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            border-radius: 12px;
            padding: 25px;
            margin-bottom: 25px;
        }
        
        .mechanism-title {
            font-size: 20px;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
            font-size: 14px;
        }
        
        .mechanism-highlight {
            background: rgba(102, 126, 234, 0.2);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #667eea;
        }
        
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 10px;
            padding: 15px;
            transition: all 0.3s;
        }
        
        .dosing-card:hover {
            transform: translateY(-3px);
            box-shadow: 0 8px 20px rgba(0,0,0,0.1);
            border-color: #667eea;
        }
        
        .dosing-label {
            font-size: 12px;
            color: #888;
            margin-bottom: 5px;
        }
        
        .dosing-value {
            font-size: 20px;
            font-weight: bold;
            color: #333;
        }
        
        .dosing-detail {
            font-size: 12px;
            color: #666;
            margin-top: 5px;
        }
        
        .timeline-container {
            margin: 25px 0;
            padding: 25px;
            background: #f8f9fa;
            border-radius: 12px;
        }
        
        .timeline-header {
            font-size: 18px;
            font-weight: bold;
            margin-bottom: 25px;
            color: #333;
        }
        
        .timeline-item {
            background: white;
            padding: 15px;
            margin-bottom: 15px;
            border-radius: 8px;
            border-left: 4px solid #667eea;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }
        
        .timeline-date {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 5px;
            font-size: 14px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
            color: #333;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .efficacy-chart {
            background: white;
            border-radius: 12px;
            padding: 25px;
            margin: 20px 0;
            box-shadow: 0 5px 15px rgba(0,0,0,0.08);
        }
        
        .chart-title {
            font-size: 18px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 250px;
            gap: 15px;
            padding: 20px 0;
        }
        
        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
        }
        
        .bar {
            width: 100%;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            border-radius: 8px 8px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 15px rgba(102, 126, 234, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -25px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 16px;
            color: #667eea;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 12px;
            color: #666;
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
            gap: 15px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f8f9fa 100%);
            border: 2px solid #e0e0e0;
            border-radius: 10px;
            padding: 15px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-3px);
            box-shadow: 0 8px 20px rgba(0,0,0,0.1);
        }
        
        .safety-percentage {
            font-size: 28px;
            font-weight: bold;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 12px;
            color: #666;
            margin-top: 8px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 12px;
            padding: 25px;
            margin: 20px 0;
        }
        
        .price-estimate {
            font-size: 28px;
            font-weight: bold;
            color: #667eea;
            margin: 15px 0;
        }
        
        .market-projection {
            display: flex;
            align-items: center;
            gap: 30px;
            margin: 20px 0;
        }
        
        .projection-value {
            font-size: 22px;
            font-weight: bold;
            color: #333;
        }
        
        .projection-label {
            font-size: 13px;
            color: #666;
        }
        
        @media (max-width: 768px) {
            .info-grid {
                grid-template-columns: 1fr;
            }
            
            .drug-nav-container {
                overflow-x: scroll;
            }
            
            .bar-chart {
                height: 200px;
            }
        }
        .bar {
    width: 100%;
    background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
    border-radius: 8px 8px 0 0;
    position: relative;
    transition: all 0.3s;
}
.bar-chart {
    display: flex;
    align-items: flex-end;
    height: 250px; /* This must be set */
    gap: 15px;
    padding: 20px 0;
}
.bar-group {
    flex: 1;
    display: flex;
    flex-direction: column;
    align-items: center;
    justify-content: flex-end;
}
    </style>
</head>
<body>
    
    <div class="main-container">
        <div class="main-header">
            <div class="main-title">Cholesterol-Lowering Competitors Analysis</div>
            <div class="main-subtitle">Comprehensive Drug Portfolio Assessment - PCSK9 & Alternative Mechanisms</div>
        </div>
        
        <div class="drug-nav-container">
            <button class="drug-nav-tab active" onclick="showDrug('statins')">Statins</button>
            <button class="drug-nav-tab" onclick="showDrug('ezetimibe')">Ezetimibe</button>
            <button class="drug-nav-tab" onclick="showDrug('bempedoic')">Bempedoic Acid</button>
            <button class="drug-nav-tab" onclick="showDrug('obicetrapib')">Obicetrapib</button>
            <button class="drug-nav-tab" onclick="showDrug('evinacumab')">Evinacumab</button>
        </div>
        
        <!-- STATINS -->
        <div id="statins" class="drug-content active">
            <div class="drug-header">
                <div class="drug-name">Statins</div>
                <div class="drug-subtitle">HMG-CoA Reductase Inhibitors</div>
                <div class="drug-company">Multiple Manufacturers (Generic)</div>
                <span class="status-badge">First-Line Therapy</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('statins', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('statins', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('statins', 'regulatory')">Clinical Evidence</button>
                <button class="nav-tab" onclick="showTab('statins', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('statins', 'commercial')">Commercial</button>
                <button class="nav-tab" onclick="showTab('statins', 'future')">Future Outlook</button>
            </div>
            
            <div class="content-area">
                <div id="statins-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üíä</div>
                                Key Examples
                            </div>
                            <ul class="info-list">
                                <li>Atorvastatin (Lipitor)</li>
                                <li>Rosuvastatin (Crestor)</li>
                                <li>Simvastatin (Zocor)</li>
                                <li>Pravastatin (Pravachol)</li>
                                <li>Lovastatin (Mevacor)</li>
                                <li>Fluvastatin (Lescol)</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üìä</div>
                                Efficacy Profile
                            </div>
                            <ul class="info-list">
                                <li>30-50% LDL-C reduction (moderate/high intensity)</li>
                                <li>25-35% CV risk reduction per mmol/L LDL drop</li>
                                <li>Proven mortality benefit</li>
                                <li>Upregulates LDL receptors</li>
                                <li>Paradoxically increases PCSK9 (feedback)</li>
                                <li>Foundation of all lipid therapy</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üéØ</div>
                                Market Position
                            </div>
                            <ul class="info-list">
                                <li>Mandatory first-line therapy globally</li>
                                <li>Generic pricing ($3-10/month)</li>
                                <li>Gateway to all advanced therapies</li>
                                <li>5-10% intolerance creates market for alternatives</li>
                                <li>Required before PCSK9 inhibitor approval</li>
                                <li>Complementary to inclisiran, not competitive</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Strategic Importance</div>
                        <div class="highlight-content">
                            Statins remain the foundational therapy that all new drugs must justify adding to, not replacing. 
                            Their low cost and proven outcomes create a high bar for cost-effectiveness. Inclisiran and other 
                            PCSK9 inhibitors are positioned as add-ons for patients not at goal on maximally tolerated statins, 
                            making statins more ally than adversary in the treatment paradigm.
                        </div>
                    </div>
                </div>
                
                <div id="statins-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Statins work by <span class="mechanism-highlight">inhibiting HMG-CoA reductase</span>, the rate-limiting 
                            enzyme in cholesterol synthesis. This leads to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Reduced intracellular cholesterol in hepatocytes</li>
                                <li>Upregulation of LDL receptors via SREBP-2 activation</li>
                                <li>Increased clearance of LDL from circulation</li>
                                <li>Compensatory increase in PCSK9 production (limiting factor)</li>
                                <li>Pleiotropic effects: anti-inflammatory, plaque stabilization</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">High-Intensity</div>
                            <div class="dosing-value">‚â•50% ‚Üì</div>
                            <div class="dosing-detail">Atorva 40-80mg, Rosuva 20-40mg</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Moderate-Intensity</div>
                            <div class="dosing-value">30-49% ‚Üì</div>
                            <div class="dosing-detail">Atorva 10-20mg, Rosuva 5-10mg</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Low-Intensity</div>
                            <div class="dosing-value"><30% ‚Üì</div>
                            <div class="dosing-detail">Simva 10mg, Prava 10-20mg</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Administration</div>
                            <div class="dosing-value">Daily</div>
                            <div class="dosing-detail">Usually evening (except atorva/rosuva)</div>
                        </div>
                    </div>
                </div>
                
                <div id="statins-regulatory" class="tab-content">
                    <div class="efficacy-chart">
                        <div class="chart-title">Landmark Trial Outcomes</div>
                        <div class="bar-chart">
                            <div class="bar-group">
                                <div class="bar" style="height: 31%;">
                                    <div class="bar-value">31%</div>
                                </div>
                                <div class="bar-label">4S Trial<br>Mortality ‚Üì</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 24%;">
                                    <div class="bar-value">24%</div>
                                </div>
                                <div class="bar-label">JUPITER<br>MACE ‚Üì</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 21%;">
                                    <div class="bar-value">21%</div>
                                </div>
                                <div class="bar-label">PROVE-IT<br>Events ‚Üì</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 35%;">
                                    <div class="bar-value">35%</div>
                                </div>
                                <div class="bar-label">Meta-analysis<br>CV Risk ‚Üì/mmol</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Evidence Base</div>
                        <div class="highlight-content">
                            Statins have the most robust outcomes data of any lipid therapy, with dozens of trials showing 
                            consistent cardiovascular and mortality benefits. This irrefutable evidence makes them the 
                            cornerstone of preventive cardiology and the benchmark against which all new therapies are measured.
                        </div>
                    </div>
                </div>
                
                <div id="statins-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">5-10%</div>
                            <div class="safety-label">Muscle Symptoms</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage"><0.1%</div>
                            <div class="safety-label">Rhabdomyolysis</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">9%</div>
                            <div class="safety-label">Diabetes Risk ‚Üë</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Rare</div>
                            <div class="safety-label">Hepatotoxicity</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚ö†Ô∏è</div>
                                Key Safety Considerations
                            </div>
                            <ul class="info-list">
                                <li>Statin-associated muscle symptoms (SAMS) main issue</li>
                                <li>True intolerance likely overestimated (nocebo effect)</li>
                                <li>Creates substantial market for alternatives</li>
                                <li>Drug interactions with CYP3A4 inhibitors</li>
                                <li>Contraindicated in pregnancy</li>
                                <li>Generally very safe with decades of use</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="statins-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">$3-10/month</div>
                        <div style="color: #666; margin-bottom: 30px;">Generic pricing globally</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">Required</div>
                                <div class="projection-label">Before PCSK9 inhibitor approval</div>
                            </div>
                            <div>
                                <div class="projection-value">Foundation</div>
                                <div class="projection-label">Of all lipid management</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Commercial Reality</div>
                        <div class="highlight-content">
                            Statins set an "essentially free and very effective" benchmark that new therapies must justify 
                            exceeding. They are gatekeepers rather than competitors - payers require maximally tolerated 
                            statin therapy before approving expensive alternatives, making them complementary to inclisiran's 
                            market positioning.
                        </div>
                    </div>
                </div>
                
                <div id="statins-future" class="tab-content">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üîÆ</div>
                                5-10 Year Outlook
                            </div>
                            <ul class="info-list">
                                <li>Will remain foundational therapy</li>
                                <li>No replacement in primary prevention</li>
                                <li>Earlier combination therapy in guidelines</li>
                                <li>Stack with PCSK9 inhibitors, not replaced</li>
                                <li>Continued generic pricing pressure</li>
                                <li>Precision medicine for intolerance</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- EZETIMIBE -->
        <div id="ezetimibe" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Ezetimibe (Zetia¬Æ)</div>
                <div class="drug-subtitle">Cholesterol Absorption Inhibitor</div>
                <div class="drug-company">Merck (now generic)</div>
                <span class="status-badge">Second-Line Add-On</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('ezetimibe', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'clinical')">Clinical Evidence</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'commercial')">Commercial</button>
                <button class="nav-tab" onclick="showTab('ezetimibe', 'future')">Future Role</button>
            </div>
            
            <div class="content-area">
                <div id="ezetimibe-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üî¨</div>
                                Key Features
                            </div>
                            <ul class="info-list">
                                <li>Blocks NPC1L1 transporter in intestine</li>
                                <li>15-25% LDL-C reduction</li>
                                <li>Once-daily oral dosing (10mg)</li>
                                <li>Generic since 2016</li>
                                <li>Often combined with statins</li>
                                <li>No muscle side effects</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üìä</div>
                                Clinical Position
                            </div>
                            <ul class="info-list">
                                <li>IMPROVE-IT: 6-7% MACE reduction</li>
                                <li>Guideline-recommended second-line</li>
                                <li>Required before PCSK9 inhibitors</li>
                                <li>Modest but proven benefit</li>
                                <li>2% absolute risk reduction</li>
                                <li>Reinforces LDL hypothesis</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üí∞</div>
                                Market Impact
                            </div>
                            <ul class="info-list">
                                <li>~$10-20/month generic</li>
                                <li>Payer-mandated step therapy</li>
                                <li>Delays need for expensive drugs</li>
                                <li>Co-formulated with statins (Vytorin)</li>
                                <li>Shrinks addressable market for PCSK9</li>
                                <li>Easy add-on for clinicians</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Competitive Dynamic</div>
                        <div class="highlight-content">
                            Ezetimibe acts as another gatekeeper before expensive therapies. Many patients achieve goals 
                            with statin + ezetimibe, never needing PCSK9 inhibitors. Its cheap generic status and benign 
                            safety profile make it an automatic second step, potentially limiting inclisiran's addressable 
                            market to those still above goal after both statin and ezetimibe.
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Ezetimibe selectively inhibits <span class="mechanism-highlight">NPC1L1 (Niemann-Pick C1-Like 1)</span> 
                            transporter at the intestinal brush border, leading to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Reduced absorption of dietary and biliary cholesterol</li>
                                <li>Decreased cholesterol delivery to liver</li>
                                <li>Compensatory upregulation of hepatic LDL receptors</li>
                                <li>Enhanced clearance of LDL from circulation</li>
                                <li>Complementary mechanism to statins</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">10 mg</div>
                            <div class="dosing-detail">Once daily</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">LDL Reduction</div>
                            <div class="dosing-value">15-25%</div>
                            <div class="dosing-detail">As monotherapy</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">With Statin</div>
                            <div class="dosing-value">+15%</div>
                            <div class="dosing-detail">Additional reduction</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Food Effect</div>
                            <div class="dosing-value">None</div>
                            <div class="dosing-detail">Can take any time</div>
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-clinical" class="tab-content">
                    <div class="timeline-container">
                        <div class="timeline-header">Key Clinical Evidence</div>
                        <div class="timeline-item">
                            <div class="timeline-date">2015</div>
                            <div class="timeline-title">IMPROVE-IT Trial</div>
                            <div class="timeline-description">
                                18,144 post-ACS patients on simvastatin ¬± ezetimibe. Added ezetimibe achieved 
                                17 mg/dL additional LDL drop and 6.4% relative risk reduction in MACE over 7 years. 
                                Absolute event reduction: 2% (32.7% vs 34.7%).
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">Ongoing</div>
                            <div class="timeline-title">Combination Studies</div>
                            <div class="timeline-description">
                                Multiple trials combining ezetimibe with newer agents (bempedoic acid as Nexlizet, 
                                obicetrapib fixed-dose combinations). Shows additive effects with different mechanisms.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">Minimal</div>
                            <div class="safety-label">Muscle Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Rare</div>
                            <div class="safety-label">Liver Issues</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Mild</div>
                            <div class="safety-label">GI Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Long-term Harms</div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Safety Advantage</div>
                        <div class="highlight-content">
                            Ezetimibe's excellent safety profile (essentially placebo-like tolerability) makes it an 
                            easy add-on that clinicians reach for reflexively. This "why not try ezetimibe first?" 
                            mentality creates another hurdle before injectable therapies are considered.
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">$10-20/month</div>
                        <div style="color: #666; margin-bottom: 30px;">Generic pricing (since 2016)</div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üè•</div>
                                Impact on PCSK9 Market
                            </div>
                            <ul class="info-list">
                                <li>Payers require ezetimibe trial first</li>
                                <li>Many patients reach goal with statin+ezetimibe</li>
                                <li>Reduces pool needing expensive therapies</li>
                                <li>Creates "step therapy" barrier</li>
                                <li>Combination pills increase usage</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="ezetimibe-future" class="tab-content">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üîÆ</div>
                                Future Role
                            </div>
                            <ul class="info-list">
                                <li>Remains baseline therapy with statins</li>
                                <li>Component of fixed-dose combinations</li>
                                <li>May combine with oral PCSK9 inhibitors</li>
                                <li>Continues as cheap generic option</li>
                                <li>Extra 15% reduction always valuable</li>
                                <li>Part of "maximize orals first" approach</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- BEMPEDOIC ACID -->
        <div id="bempedoic" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Bempedoic Acid (Nexletol¬Æ)</div>
                <div class="drug-subtitle">ACL Inhibitor - Oral Non-Statin</div>
                <div class="drug-company">Esperion Therapeutics</div>
                <span class="status-badge">FDA Approved with CV Outcomes</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('bempedoic', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'regulatory')">Regulatory & Trials</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'commercial')">Commercial</button>
                <button class="nav-tab" onclick="showTab('bempedoic', 'future')">Future Outlook</button>
            </div>
            
            <div class="content-area">
                <div id="bempedoic-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üéØ</div>
                                Key Differentiators
                            </div>
                            <ul class="info-list">
                                <li>First oral non-statin with CV outcomes</li>
                                <li>No muscle side effects (liver-specific)</li>
                                <li>18-25% LDL reduction</li>
                                <li>13% MACE reduction proven (CLEAR)</li>
                                <li>23% MI reduction in statin-intolerant</li>
                                <li>Once-daily oral (180mg)</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚úÖ</div>
                                Regulatory Milestones
                            </div>
                            <ul class="info-list">
                                <li>FDA approved Feb 2020</li>
                                <li>EMA approved 2020 (Nilemdo)</li>
                                <li>CLEAR Outcomes positive March 2023</li>
                                <li>CV risk reduction label 2023</li>
                                <li>No CRLs or major delays</li>
                                <li>Orphan designation for HoFH</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üèÜ</div>
                                Competitive Position
                            </div>
                            <ul class="info-list">
                                <li>Fills statin-intolerant niche</li>
                                <li>Oral alternative to injections</li>
                                <li>Now has outcomes data advantage</li>
                                <li>Combo with ezetimibe (Nexlizet)</li>
                                <li>May become gatekeeper to PCSK9</li>
                                <li>$400/month vs $6000+ for mAbs</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Market Impact on Inclisiran</div>
                        <div class="highlight-content">
                            With proven CV outcomes, bempedoic acid can now market itself as preventing heart attacks - 
                            something inclisiran cannot yet claim. Payers may require trying bempedoic acid (¬±ezetimibe) 
                            before approving expensive injectables, creating another step therapy barrier. The 35% LDL 
                            reduction with bempedoic+ezetimibe may satisfy many patients, shrinking inclisiran's addressable market.
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Bempedoic acid inhibits <span class="mechanism-highlight">ATP citrate lyase (ACL)</span>, 
                            an enzyme upstream of HMG-CoA reductase in cholesterol synthesis. Key features:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Prodrug activated by ACSVL1 enzyme (liver-specific)</li>
                                <li>Not activated in muscle tissue (avoiding myopathy)</li>
                                <li>Reduces hepatic cholesterol synthesis</li>
                                <li>Upregulates LDL receptors</li>
                                <li>Complementary to statin mechanism</li>
                                <li>Can be used with or without statins</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">180 mg</div>
                            <div class="dosing-detail">Once daily</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">LDL Reduction</div>
                            <div class="dosing-value">18-25%</div>
                            <div class="dosing-detail">Monotherapy</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">With Ezetimibe</div>
                            <div class="dosing-value">35-38%</div>
                            <div class="dosing-detail">Nexlizet combo</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Time to Effect</div>
                            <div class="dosing-value">4 weeks</div>
                            <div class="dosing-detail">Maximum LDL drop</div>
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-regulatory" class="tab-content">
                    <div class="timeline-container">
                        <div class="timeline-header">CLEAR Outcomes Trial Results</div>
                        <div class="timeline-item">
                            <div class="timeline-date">March 2023</div>
                            <div class="timeline-title">Primary Endpoint Met</div>
                            <div class="timeline-description">
                                13,970 statin-intolerant patients, 3.4 years follow-up. 13% reduction in 4-point MACE 
                                (11.7% vs 13.3%, p=0.004). Absolute risk reduction: 1.6%.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">Key Results</div>
                            <div class="timeline-title">Component Outcomes</div>
                            <div class="timeline-description">
                                ‚Ä¢ Myocardial infarction: 23% reduction (4.7% vs 6.1%)<br>
                                ‚Ä¢ Coronary revascularization: 19% reduction<br>
                                ‚Ä¢ Stroke: 19% reduction (not significant alone)<br>
                                ‚Ä¢ CV death: No difference<br>
                                ‚Ä¢ LDL reduction: 21% placebo-adjusted
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">2023</div>
                            <div class="timeline-title">Label Expansion</div>
                            <div class="timeline-description">
                                FDA approved new indication to reduce risk of MI, stroke, and coronary revascularization 
                                in adults with ASCVD or HeFH. First non-statin oral with CV risk reduction claim.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">3.5%</div>
                            <div class="safety-label">Gout (vs 2.1% placebo)</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">0.5%</div>
                            <div class="safety-label">Tendon Rupture</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">‚Üë</div>
                            <div class="safety-label">Uric Acid</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Muscle Issues</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚ö†Ô∏è</div>
                                Safety Considerations
                            </div>
                            <ul class="info-list">
                                <li>Raises uric acid - monitor for gout</li>
                                <li>Tendon rupture warning (Achilles)</li>
                                <li>Small increase in creatinine/BUN</li>
                                <li>No hepatotoxicity</li>
                                <li>No myalgia (liver-specific activation)</li>
                                <li>Generally well tolerated</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">~$400/month</div>
                        <div style="color: #666; margin-bottom: 30px;">US list price (significantly less than PCSK9 mAbs)</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">Growing</div>
                                <div class="projection-label">Post-outcomes uptake</div>
                            </div>
                            <div>
                                <div class="projection-value">2033</div>
                                <div class="projection-label">Patent expiry estimate</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Payer Dynamics</div>
                        <div class="highlight-content">
                            With outcomes data, payers may mandate trying bempedoic acid before expensive injectables. 
                            At $400/month vs $6000+ for PCSK9 mAbs, it's an attractive intermediate option. Could become 
                            standard step therapy: statin ‚Üí +ezetimibe ‚Üí +bempedoic ‚Üí then PCSK9 if needed.
                        </div>
                    </div>
                </div>
                
                <div id="bempedoic-future" class="tab-content">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üîÆ</div>
                                Future Positioning
                            </div>
                            <ul class="info-list">
                                <li>Entrenched in statin-intolerant segment</li>
                                <li>Part of oral combination strategies</li>
                                <li>Generic by early 2030s</li>
                                <li>May combine with oral PCSK9 inhibitors</li>
                                <li>Triple oral therapy possible</li>
                                <li>Further squeezes injectable market</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- OBICETRAPIB -->
        <div id="obicetrapib" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Obicetrapib</div>
                <div class="drug-subtitle">Next-Generation CETP Inhibitor</div>
                <div class="drug-company">NewAmsterdam Pharma</div>
                <span class="status-badge">EMA Review - Phase III</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('obicetrapib', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'regulatory')">Regulatory Status</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'clinical')">Clinical Trials</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('obicetrapib', 'commercial')">Commercial</button>
            </div>
            
            <div class="content-area">
                <div id="obicetrapib-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üî¨</div>
                                Key Features
                            </div>
                            <ul class="info-list">
                                <li>35-45% LDL reduction as monotherapy</li>
                                <li>~50% with ezetimibe combo</li>
                                <li>Raises HDL >100%</li>
                                <li>Once-daily oral (10mg)</li>
                                <li>No blood pressure effects</li>
                                <li>Potential cognitive benefits (p-tau‚Üì)</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üìä</div>
                                CETP Class History
                            </div>
                            <ul class="info-list">
                                <li>Torcetrapib: Failed (‚Üëmortality)</li>
                                <li>Anacetrapib: 9% MACE‚Üì but shelved</li>
                                <li>Evacetrapib: Failed (no benefit)</li>
                                <li>Obicetrapib: Clean safety profile</li>
                                <li>Solves prior class issues</li>
                                <li>"Rebirth of CETP inhibitors"</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üéØ</div>
                                Strategic Position
                            </div>
                            <ul class="info-list">
                                <li>EMA MAA validated Aug 2025</li>
                                <li>EU approval possible 2024/25</li>
                                <li>PREVAIL outcomes trial ongoing</li>
                                <li>Menarini partnership for Europe</li>
                                <li>Fixed-dose combo with ezetimibe</li>
                                <li>Different mechanism vs PCSK9</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Competitive Threat to Inclisiran</div>
                        <div class="highlight-content">
                            An all-oral triple therapy (statin + obicetrapib + ezetimibe) could rival injectable PCSK9 
                            inhibitor efficacy. With ~50% LDL reduction from obicetrapib+ezetimibe combo, many patients 
                            might achieve goals without injections. If approved before oral PCSK9 inhibitors, could gain 
                            foothold as the preferred oral intensification option.
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Obicetrapib inhibits <span class="mechanism-highlight">CETP (Cholesteryl Ester Transfer Protein)</span>, 
                            leading to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>Reduced transfer of cholesteryl esters from HDL to VLDL/LDL</li>
                                <li>Enhanced reverse cholesterol transport</li>
                                <li>Indirect upregulation of LDL receptors</li>
                                <li>Substantial HDL-C increase (>100%)</li>
                                <li>Reduction in VLDL remnants</li>
                                <li>No off-target aldosterone effects (unlike torcetrapib)</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">10 mg</div>
                            <div class="dosing-detail">Once daily</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">LDL Reduction</div>
                            <div class="dosing-value">35-45%</div>
                            <div class="dosing-detail">On top of statin</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">With Ezetimibe</div>
                            <div class="dosing-value">~50%</div>
                            <div class="dosing-detail">Fixed combo</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">HDL Increase</div>
                            <div class="dosing-value">>100%</div>
                            <div class="dosing-detail">Substantial rise</div>
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-regulatory" class="tab-content">
                    <div class="timeline-container">
                        <div class="timeline-header">Regulatory Timeline</div>
                        <div class="timeline-item">
                            <div class="timeline-date">2023-2024</div>
                            <div class="timeline-title">Phase 3 Trials Complete</div>
                            <div class="timeline-description">
                                BROADWAY (2,500 pts), BROOKLYN (HeFH), and TANDEM (combo) trials completed. 
                                Strong LDL reduction without safety issues seen with prior CETP inhibitors.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">August 2025</div>
                            <div class="timeline-title">EMA MAA Validated</div>
                            <div class="timeline-description">
                                Marketing authorization application accepted for review by EMA for both obicetrapib 
                                monotherapy and fixed-dose combination with ezetimibe.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">2024/25 (Expected)</div>
                            <div class="timeline-title">EU Approval</div>
                            <div class="timeline-description">
                                Potential approval based on LDL surrogate endpoint. FDA likely requires outcomes data.
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">~2026</div>
                            <div class="timeline-title">PREVAIL Outcomes Trial</div>
                            <div class="timeline-description">
                                Large cardiovascular outcomes trial to determine MACE reduction. Critical for FDA approval 
                                and broader adoption.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-clinical" class="tab-content">
                    <div class="efficacy-chart">
                        <div class="chart-title">Phase 3 LDL-C Reduction Results</div>
                        <div class="bar-chart">
                            <div class="bar-group">
                                <div class="bar" style="height: 33%;">
                                    <div class="bar-value">33%</div>
                                </div>
                                <div class="bar-label">BROADWAY<br>84 days</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 45%;">
                                    <div class="bar-value">45%</div>
                                </div>
                                <div class="bar-label">BROOKLYN<br>HeFH</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 50%;">
                                    <div class="bar-value">50%</div>
                                </div>
                                <div class="bar-label">TANDEM<br>+Ezetimibe</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Exploratory Finding</div>
                        <div class="highlight-content">
                            BROADWAY substudy showed 1.1% reduction in CSF p-tau217 (Alzheimer's biomarker) vs placebo 
                            increase, suggesting potential neuroprotective effects. While exploratory, this could provide 
                            unique differentiation if confirmed in further studies.
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">No ‚Üë</div>
                            <div class="safety-label">Blood Pressure</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Liver Fat</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Mild</div>
                            <div class="safety-label">GI Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Short</div>
                            <div class="safety-label">Half-life (no accumulation)</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚úÖ</div>
                                Safety Advantages vs Prior CETP
                            </div>
                            <ul class="info-list">
                                <li>No blood pressure increase (vs torcetrapib)</li>
                                <li>No tissue accumulation (vs anacetrapib)</li>
                                <li>No electrolyte disturbances</li>
                                <li>Well-tolerated in trials</li>
                                <li>Main AEs: nausea, headache (mild)</li>
                                <li>Solved class safety issues</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="obicetrapib-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">~$4,000/year</div>
                        <div style="color: #666; margin-bottom: 30px;">Projected pricing (similar to bempedoic acid)</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">2024/25</div>
                                <div class="projection-label">EU launch expected</div>
                            </div>
                            <div>
                                <div class="projection-value">Oral</div>
                                <div class="projection-label">Advantage vs injections</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Market Positioning</div>
                        <div class="highlight-content">
                            If approved before oral PCSK9 inhibitors, obicetrapib could capture the "next oral after 
                            statin+ezetimibe" position. Fixed-dose combination with ezetimibe offers ~50% LDL reduction 
                            in one pill. Different mechanism allows combination with PCSK9 inhibitors for extreme LDL lowering.
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- EVINACUMAB -->
        <div id="evinacumab" class="drug-content">
            <div class="drug-header">
                <div class="drug-name">Evinacumab (Evkeeza¬Æ)</div>
                <div class="drug-subtitle">ANGPTL3 Monoclonal Antibody</div>
                <div class="drug-company">Regeneron/Ultragenyx</div>
                <span class="status-badge">FDA/EMA Approved (HoFH Only)</span>
            </div>
            
            <div class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('evinacumab', 'overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'mechanism')">Mechanism & Dosing</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'clinical')">Clinical Evidence</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'safety')">Safety Profile</button>
                <button class="nav-tab" onclick="showTab('evinacumab', 'commercial')">Commercial</button>
            </div>
            
            <div class="content-area">
                <div id="evinacumab-overview" class="tab-content active">
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üß¨</div>
                                Unique Features
                            </div>
                            <ul class="info-list">
                                <li>LDL receptor-independent mechanism</li>
                                <li>47% LDL reduction in HoFH</li>
                                <li>Works when PCSK9 inhibitors fail</li>
                                <li>Monthly IV infusion (15mg/kg)</li>
                                <li>Orphan drug designation</li>
                                <li>Only for homozygous FH</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üè•</div>
                                Clinical Niche
                            </div>
                            <ul class="info-list">
                                <li>HoFH prevalence: ~1 in 1 million</li>
                                <li>Approved age ‚â•12 years</li>
                                <li>Add-on to other therapies</li>
                                <li>132 mg/dL absolute LDL drop</li>
                                <li>Life-saving for extreme cases</li>
                                <li>Specialist administration only</li>
                            </ul>
                        </div>
                        
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">üí∞</div>
                                Economic Profile
                            </div>
                            <ul class="info-list">
                                <li>~$450,000/year list price</li>
                                <li>Ultra-orphan drug pricing</li>
                                <li>Insurance restricted to HoFH</li>
                                <li>Tiny commercial market</li>
                                <li>Not competitor to inclisiran</li>
                                <li>Complementary in extreme cases</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Relevance to Inclisiran</div>
                        <div class="highlight-content">
                            Evinacumab doesn't compete with inclisiran - it addresses cases where PCSK9 inhibition fails 
                            (null LDL receptors). Shows that different mechanisms (ANGPTL3) can lower LDL independently 
                            of LDLR, providing options for genetic conditions requiring orthogonal approaches. More 
                            complementary than competitive in the treatment landscape.
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-mechanism" class="tab-content">
                    <div class="mechanism-section">
                        <div class="mechanism-title">
                            <div class="info-icon">‚öôÔ∏è</div>
                            Mechanism of Action
                        </div>
                        <div class="mechanism-content">
                            Evinacumab blocks <span class="mechanism-highlight">ANGPTL3 (Angiopoietin-like 3)</span>, 
                            a protein that inhibits lipoprotein and endothelial lipases:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li>LDL receptor-independent pathway</li>
                                <li>Enhanced clearance of VLDL remnants</li>
                                <li>Reduced conversion of VLDL to LDL</li>
                                <li>Dramatically lowers triglycerides</li>
                                <li>Works even with null LDL receptors</li>
                                <li>Complementary to PCSK9 inhibition</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Dose</div>
                            <div class="dosing-value">15 mg/kg</div>
                            <div class="dosing-detail">Weight-based</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Frequency</div>
                            <div class="dosing-value">Monthly</div>
                            <div class="dosing-detail">Every 4 weeks</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Route</div>
                            <div class="dosing-value">IV</div>
                            <div class="dosing-detail">60-min infusion</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Setting</div>
                            <div class="dosing-value">Clinic</div>
                            <div class="dosing-detail">Infusion center</div>
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-clinical" class="tab-content">
                    <div class="efficacy-chart">
                        <div class="chart-title">ELIPSE-HoFH Trial Results</div>
                        <div class="bar-chart">
                            <div class="bar-group">
                                <div class="bar" style="height: 47%;">
                                    <div class="bar-value">47%</div>
                                </div>
                                <div class="bar-label">LDL-C<br>Reduction</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 132%; max-height: 90%;">
                                    <div class="bar-value">132 mg/dL</div>
                                </div>
                                <div class="bar-label">Absolute<br>LDL Drop</div>
                            </div>
                            <div class="bar-group">
                                <div class="bar" style="height: 50%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                    <div class="bar-value">50%</div>
                                </div>
                                <div class="bar-label">Triglyceride<br>Reduction</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">No Outcomes Trial</div>
                        <div class="highlight-content">
                            HoFH is too rare for outcomes studies. Efficacy judged on LDL reduction alone, as any 
                            substantial lowering in HoFH is assumed life-saving given extreme baseline risk. Regulatory 
                            approval based on surrogate endpoint was straightforward given unmet need.
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-safety" class="tab-content">
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-percentage">Mild</div>
                            <div class="safety-label">Infusion Reactions</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">None</div>
                            <div class="safety-label">Liver Fat ‚Üë</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">No</div>
                            <div class="safety-label">Muscle Effects</div>
                        </div>
                        <div class="safety-card">
                            <div class="safety-percentage">Good</div>
                            <div class="safety-label">Overall Tolerance</div>
                        </div>
                    </div>
                    
                    <div class="info-grid">
                        <div class="info-card">
                            <div class="info-card-title">
                                <div class="info-icon">‚úÖ</div>
                                Safety Profile
                            </div>
                            <ul class="info-list">
                                <li>Main AEs: infusion reactions (mild)</li>
                                <li>No liver enzyme elevation</li>
                                <li>No muscle toxicity</li>
                                <li>Unlike antisense, no liver fat increase</li>
                                <li>No vitamin deficiency seen</li>
                                <li>4 years post-approval, no new signals</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div id="evinacumab-commercial" class="tab-content">
                    <div class="commercial-section">
                        <div class="price-estimate">~$450,000/year</div>
                        <div style="color: #666; margin-bottom: 30px;">Ultra-orphan drug pricing</div>
                        
                        <div class="market-projection">
                            <div>
                                <div class="projection-value">~1/million</div>
                                <div class="projection-label">HoFH prevalence</div>
                            </div>
                            <div>
                                <div class="projection-value">Specialty</div>
                                <div class="projection-label">Lipid clinics only</div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="highlight-box">
                        <div class="highlight-title">Not a Competitor</div>
                        <div class="highlight-content">
                            Evinacumab exemplifies targeting a different pathway (ANGPTL3) for cases where PCSK9/LDLR 
                            approaches fail. It's a highly specialized tool for rare genetic conditions, not a threat 
                            to inclisiran's mainstream market. Shows the diversity of mechanisms being explored in 
                            lipid management.
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showDrug(drugId) {
            // Hide all drug contents
            const drugContents = document.querySelectorAll('.drug-content');
            drugContents.forEach(content => content.classList.remove('active'));
            
            // Remove active class from all drug nav tabs
            const drugTabs = document.querySelectorAll('.drug-nav-tab');
            drugTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected drug content
            document.getElementById(drugId).classList.add('active');
            
            // Add active class to clicked drug tab
            event.target.classList.add('active');
            
            // Reset to first sub-tab when switching drugs
            const firstSubTab = document.querySelector(`#${drugId} .nav-tab`);
            if (firstSubTab) {
                firstSubTab.click();
            }
        }
        
        function showTab(drugId, tabName) {
            // Hide all tabs for this drug
            const tabs = document.querySelectorAll(`#${drugId} .tab-content`);
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs for this drug
            const navTabs = document.querySelectorAll(`#${drugId} .nav-tab`);
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(`${drugId}-${tabName}`).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
    </script>
</body>
</html>